• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

POINT Biopharma Global Inc. - Common Stock (NQ:PNT)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 12.49 (70)
Ask (Size) 12.51 (49)
Prev. Close 12.50
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 90,121,794
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned ↗
December 27, 2023
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole... 
Via Benzinga
News headline image
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug ↗
December 19, 2023
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c 
Via Benzinga

Performance

More News

Read More
News headline image
Why is Prostate Cancer Focused Lantheus Stock Trading Lower Today? ↗
December 18, 2023
Via Benzinga
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
November 29, 2023
Via FinancialNewsMedia
Topics Death
News headline image
Recap: POINT Biopharma Global Q3 Earnings ↗
November 13, 2023
Via Benzinga
News headline image
Top 5 Health Care Stocks That May Collapse In November ↗
November 17, 2023
Via Benzinga
News headline image
7 Healthcare Stocks That Are Poised to Become the Next Unicorns ↗
November 09, 2023
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗
October 24, 2023
Via Benzinga
News headline image
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
October 17, 2023
Via PressReach
News headline image
POINT BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of POINT Biopharma Global, Inc. - PNT
October 06, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Stock Market Ends On High Note Even As Yields Soar; Tesla In Focus: Weekly Review ↗
October 06, 2023
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023 ↗
October 06, 2023
Via Benzinga
News headline image
Why Point BioPharma Global Stock Skyrocketed 86% This Week ↗
October 05, 2023
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2023 ↗
October 04, 2023
Via Benzinga
News headline image
Why Eli Lilly Stock Was Looking Sickly Today ↗
October 03, 2023
Via The Motley Fool
News headline image
Crude Oil Moves Higher; POINT Biopharma Global Shares Jump ↗
October 03, 2023
Via Benzinga
Topics Stocks
News headline image
Why Shares of Point Biopharma Global Are Soaring Tuesday ↗
October 03, 2023
Via The Motley Fool
News headline image
Why Getty Images Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
October 03, 2023
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
October 03, 2023
Via Benzinga
News headline image
Nasdaq Down Over 200 Points; US Job Openings Rise In August ↗
October 03, 2023
Via Benzinga
Topics Stocks
News headline image
Point Biopharma Stock Nearly Doubles On Eli Lilly Deal ↗
October 03, 2023
Via Talk Markets
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Vericity, Inc. (Nasdaq - VERY), POINT Biopharma Global, Inc. (Nasdaq - PNT), Blue Apron Holdings, Inc. (Nasdaq - APRN), Chico’s FAS, Inc. (NYSE - CHS)
October 03, 2023
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories ↗
October 03, 2023
Via Benzinga
News headline image
Vericity, POINT Biopharma Global, Oddity Tech And Other Big Stocks Moving Higher On Tuesday ↗
October 03, 2023
Via Benzinga
Topics Stocks
News headline image
Dow Falls Over 100 Points; McCormick Sales Miss Views ↗
October 03, 2023
Via Benzinga
Topics Earnings Stocks

Frequently Asked Questions

Is POINT Biopharma Global Inc. - Common Stock publicly traded?
Yes, POINT Biopharma Global Inc. - Common Stock is publicly traded.
What exchange does POINT Biopharma Global Inc. - Common Stock trade on?
POINT Biopharma Global Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for POINT Biopharma Global Inc. - Common Stock?
The ticker symbol for POINT Biopharma Global Inc. - Common Stock is PNT on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap